uniQure N.V. (QURE) AI Stock Analysis

uniQure N.V. is a gene therapy company founded in 1998 and based in Amsterdam, the Netherlands. The company focuses on developing transformative treatments for patients with severe genetic diseases. Its flagship program, Etranacogene dezaparvovec (AMT-061), is in Phase III HOPE-B pivotal trials for the treatment of hemophilia B. uniQure's clinical pipeline also includes AMT-130 in Phase I/II trials for Huntington's disease, alongside AMT-060 for hemophilia B, AMT-210 for Parkinson's disease, AMT-260 for temporal lobe epilepsy, AMT-240 for Alzheimer's disease in preclinical stages, and AMT-161 for amyotrophic lateral sclerosis.

uniQure has experienced significant volatility in top-line results over recent years. Revenue declined from $524.0M in FY2021 to $106.5M in FY2022 and $15.8M in FY2023, before rising to $27.1M in FY2024 and falling 40.6% to $16.1M in FY2025. Across the five-year period from FY2020 to FY2025, revenue contracted at a compound annual rate of -15.6%. In FY2025, the company recorded a net income of -$199.0M and an operating margin of -1166.8%, compared to an R&D expense of $140.7M. Over the trailing twelve months, revenue reached $18.7M with an operating margin of -872.2% and EPS of -$4.03. For the latest quarter ended June 30, 2026, quarterly revenue increased 11.0% year-over-year while quarterly earnings fell 18.2%.

As of June 30, 2026, uniQure held $810.3M in cash and short-term investments against total debt of $62.8M, resulting in net cash of $747.5M. Total assets stood at $985.1M and shareholders' equity was $324.1M, supported by a current ratio of 10.01 and a debt-to-equity ratio of 0.19. In FY2025, operating cash flow was -$178.0M and free cash flow was -$178.0M, with capital expenditures totaling $439,000. Additionally, the company's share count expanded by 41.4% over the past 5 years.

uniQure trades at an enterprise value of $2.22B and a market cap of $1.51B. Its price-to-sales ratio is 80.9x, which stands substantially higher than the 4.1x median of its US-listed Healthcare peers. The company's forward P/E is 27.9x compared to the peer median of 17.3x, while its EV/EBITDA multiple is 1.4x against the peer median of 12.0x. Over the past year, the stock fell 63.7%, trailing the S&P 500 (SPY) return of 16.8%. Over a 5-year period, the stock fell 27.5% compared to an 83.0% gain for the S&P 500.

Wall Street analysts maintain 10 Strong Buy, 1 Buy, and 2 Hold ratings on QURE, with no Sell ratings. The mean price target is $61.43, representing a 182.0% upside compared to the last close of $21.78. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $21.1M and EPS of -$3.44. For the next fiscal year, 11 analysts project revenue to expand 356.1% to $96.2M. Over the last 4 quarters, uniQure has beaten EPS estimates 2 times, with the next earnings release scheduled for November 9, 2026.

This page is an AI-written research summary of uniQure N.V. (QURE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: QURE income statement, QURE balance sheet, QURE key metrics, QURE analyst forecast, QURE chart. See the QURE stock overview for the latest quote and news.